Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Decitabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Adverse reactions
Most Recent Events
- 13 Feb 2024 Planned number of patients changed from 33 to 85.
- 13 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 13 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.